Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy

por Yu, Shufei, Zhang, Wencheng, Ni, Wenjie, Xiao, Zefen, Wang, Xin, Zhou, Zongmei, Feng, Qinfu, Chen, Dongfu, Liang, Jun, Fang, Dekang, Mao, Yousheng, Gao, Shugeng, Li, Yexiong, He, Jie
Publicado 2016

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squ...

por Ni, Wenjie, Yu, Shufei, Zhang, Wencheng, Xiao, Zefen, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Liang, Jun, Lv, Jima, Gao, Shugeng, Mao, Yousheng, Xue, Qi, Sun, Kelin, Liu, Xiangyang, Fang, Dekang, Li, Jian, Wang, Dali
Publicado 2020

Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two‐center study

por Ni, Wenjie, Chen, Junqiang, Xiao, Zefen, Yu, Shufei, Zhang, Wencheng, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Chen, Xiaohui, Lin, Yu, Zhu, Kunshou, Gao, Shugeng, Xue, Qi, Mao, Yousheng, Cheng, Guiyu, Sun, Kelin, Liu, Xiangyang, Fang, Dekang
Publicado 2019

A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis

por Deng, Wei, Wang, Qifeng, Xiao, Zefen, Tan, Lijun, Yang, Zhao, Zhou, Zongmei, Zhang, Hongxing, Chen, Dongfu, Feng, Qinfu, Liang, Jun, Li, Yexiong, He, Jie, Gao, Shugeng, Sun, Kelin, Cheng, Guiyu, Liu, Xiangyang, Fang, Dekang, Xue, Qi, Mao, Yousheng, Wang, Dali, Li, Jian
Publicado 2017

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma

por Han, Weiming, Deng, Wei, Wang, Qifeng, Ni, Wenjie, Li, Chen, Zhou, Zongmei, Liang, Jun, Chen, Dongfu, Feng, Qinfu, Bi, Nan, Zhang, Tao, Wang, Xin, Deng, Lei, Wang, Wenqing, Liu, Wenyang, Wang, Jianyang, Xue, Qi, Mao, Yousheng, Liu, Xiangyang, Fang, Dekang, Li, Jian, Wang, Dali, Zhao, Jun, Xiao, Zefen
Publicado 2022